Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Dare (Details)

v3.24.2.u1
Royalty and Commercial Payment Purchase Agreements - Dare (Details) - USD ($)
$ in Thousands
 6 Months Ended
Apr. 29, 2024
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 37,000 $ 14,650  
Receipts under RPAs, AAAs and CPPAs   16,741 $ 2,934  
Long-term royalty and commercial payment receivables   69,731   $ 57,952
Short-term royalty and commercial payment receivables   14,257   $ 14,215
Royalty Purchase Agreement | Dare        
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs $ 22,000 22,000    
Percentage of remaining royalties 100.00%      
Payable on milestone $ 11,000      
Specified amount of each successive receipt that requires milestone payment 22,000      
Return threshold $ 88,000      
Short-term royalty and commercial payment receivables   0    
Amount of allowance for credit losses   $ 0    
Royalty Purchase Agreement | Dare | OVAPRENE        
Agreements        
Royalties entity has right to receive (as a percent) 4.00%      
Royalty Purchase Agreement | Dare | OVAPRENE | Upon achievement of a pre-specified return threshold        
Agreements        
Royalties entity has right to receive (as a percent) 2.50%      
Royalty Purchase Agreement | Dare | Sildenafil Cream        
Agreements        
Royalties entity has right to receive (as a percent) 2.00%      
Royalty Purchase Agreement | Dare | Sildenafil Cream | Upon achievement of a pre-specified return threshold        
Agreements        
Royalties entity has right to receive (as a percent) 1.25%